What's legal,
where it stands.
BPC-157 is in regulatory flux. Below: a snapshot of legal status by jurisdiction, a curated timeline of what changed when, the latest news from authoritative sources, and an honest breakdown of how people are actually getting it today.
This page is informational, compiled from public sources. It is not legal advice or medical advice. Flint does not endorse any vendor or supplier. Always speak with a licensed clinician before considering any peptide.
Where BPC-157 stands legally
United States
BPC-157 has no FDA approval for any human use. As of October 2023 it is excluded from the Section 503A bulks list, meaning legitimate compounding pharmacies can no longer make it from bulk APIs. The remaining channels (telehealth, research-only vendors) operate in legal gray space.
Source ↗United Kingdom / EU
Not authorised as a medicine by the MHRA (UK) or EMA (EU). Sale for human consumption is illegal. Imported as a research chemical at customs risk.
Source ↗Australia
The Therapeutic Goods Administration (TGA) places BPC-157 in Schedule 10 of the Poisons Standard — substances of such danger to health that they should not be available for supply. Possession and supply for human use is illegal.
Source ↗Canada
Health Canada has not authorised BPC-157 for therapeutic use. Sale for human consumption is not legal; some compounding pharmacies have made it on a case-by-case prescriber order.
Source ↗WADA (Olympic / pro sports)
World Anti-Doping Agency added BPC-157 to S0 (non-approved substances) on the Prohibited List. In-competition and out-of-competition use is banned for athletes subject to the WADA code.
Source ↗Japan
Not approved by PMDA. Personal import is technically permitted under Yakkan Shoumei but the substance has no clinical authorisation.
Source ↗Regulatory timeline
- 2026-04Status
Current US legal status
BPC-157 has no FDA-approved indication for human use. It is not a controlled substance. It is not legally sold for human consumption. The remaining channels are: (1) telehealth clinics that prescribe via individualized exemptions, (2) the "research-only / not for human use" vendor market — a legal gray area that customs and the FDA can disrupt at any time, and (3) a small number of foreign pharmacies. None of these are FDA-sanctioned therapeutic routes.
FDA: buying medicines ↗ - 2026-04-16FDA
Federal Register: PCAC peptide review notice published
FDA publishes the Federal Register notice scheduling the July 2026 PCAC meeting and announcing a second PCAC meeting before February 2027 covering five additional peptides (GHK-Cu, Melanotan II, Cathelicidin LL-37, Dihexa acetate, and Pegylated MGF). Substances actually placed on Category 1 would be removed from Category 2 "within seven calendar days."
Federal Register ↗ - 2026-07-23FDA
PCAC to reconsider BPC-157 for Category 1 (compounding allowed)
FDA's Pharmacy Compounding Advisory Committee is scheduled to meet July 23–24, 2026 at White Oak (Silver Spring, MD) to review BPC-157, KPV, TB-500, and MOTS-C for potential Category 1 inclusion on the 503A bulk drug substances list. A Category 1 placement would effectively reverse the October 2023 decision and reopen the compounding-pharmacy channel. PCAC recommendations are non-binding; even with a positive vote, formal rulemaking before pharmacies could compound is likely 12+ months out. Public written comments due by July 9, 2026; oral presentation notifications by June 30, 2026 (docket FDA-2025-N-6895).
FDA Law Blog · Apr 2026 ↗ - 2025Research
First small human pilot trials emerge
A handful of small human studies appear in PubMed — including IV safety trials and condition-specific pilots (e.g. interstitial cystitis). Sample sizes are tiny (n<25 typical) and effect sizes vary, but they represent the first peer-reviewed human data on BPC-157 outcomes.
PubMed: human BPC-157 trials ↗ - 2024-2025Telehealth
Telehealth peptide clinics adapt
After the FDA decision, the telehealth peptide market splits. Compliant clinics drop BPC-157 entirely; less-compliant operators continue offering it under various legal interpretations (e.g., out-of-pocket prescription via foreign pharmacies). Customers report inconsistent access and pricing.
r/Peptides ongoing discussions ↗ - 2024TGA
Australia confirms BPC-157 in Schedule 10 (banned)
Australia's Therapeutic Goods Administration places BPC-157 in Schedule 10 of the Poisons Standard — substances of such danger to health that they should not be available for supply. Possession and supply for human use is illegal in AU.
TGA scheduling ↗ - 2024-01Industry
Major US compounding pharmacies stop production
Within months of the FDA decision, the largest US compounding networks (e.g. Empower Pharmacy, Tailor Made Compounding) halt BPC-157 production. Some clinicians shift patients to alternative peptides (TB-500, GHK-Cu) that remain available through compounding pharmacies on a case-by-case basis.
Industry coverage ↗ - 2023-10FDA
FDA places BPC-157 on Category 2
FDA accepts the PCAC recommendation. BPC-157 is placed in Category 2 of the bulks list — substances that nominate-but-do-not-meet-the-criteria. This effectively closes the door to legal compounding pharmacy access in the US: 503A pharmacies can no longer compound BPC-157 from bulk APIs.
FDA bulks list status ↗ - 2023-09FDA
FDA advisory committee rejects BPC-157 for compounding
The Pharmacy Compounding Advisory Committee (PCAC) reviews BPC-157 and recommends against placing it on the Section 503A bulks list. Their reasoning cites limited safety data, no FDA-approved drug containing the substance, and concerns about quality control of bulk drug substance.
FDA PCAC 2023 meeting materials ↗ - 2018WADA
WADA bans BPC-157 for athletes
The World Anti-Doping Agency adds BPC-157 to category S0 of its Prohibited List — "non-approved substances." In-competition and out-of-competition use is banned. Almost no Olympic / professional athlete can use it without facing a doping violation.
WADA Prohibited List ↗ - 1991Discovery
BPC-157 first synthesized
Predrag Sikiric and colleagues at the University of Zagreb isolate and characterize BPC (Body Protection Compound) — a 15-amino-acid peptide derived from a protective protein found in human gastric juice. The lab will publish the bulk of preclinical research over the next 30+ years.
PubMed: Sikiric BPC-157 ↗
Recent legality signal
Federal Register filings + research papers + community discussions filtered for regulatory keywords. No editorial. 44 items.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
This review discusses the potential of therapeutic peptides, including BPC-157, in addressing various aspects of aging, and concludes that while FDA-approved peptides show promise, investigational peptides require further validation. The review highlights the need for rigorous clinical trials to establish safety and efficacy for healthspan extension.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
This review discusses the use of peptides, including BPC-157, in sports medicine, highlighting the lack of rigorous human safety data for many unapproved peptides. It provides a framework for navigating patient discussions about peptides and promoting evidence-based practices.
Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.
This review suggests that BPC 157 may serve as a cytoprotective mediator to counteract both hemorrhage and thrombosis, and promote wound healing and arrhythmia control. The paper concludes that BPC 157 has a unique ability to provide full cytoprotective effects, unlike conventional agents which offer only partial protection.
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.
BPC-157, a synthetic peptide, has shown promise in preclinical models for tissue repair and pain management, with potential therapeutic value for various conditions, but human research is limited and more rigorous trials are needed. The review concludes that BPC-157 is a promising candidate for regenerative medicine, but comprehensive evaluation is required before clinical translation can be recommended.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
This review of injectable peptide therapy found that while BPC-157 and other peptides show potential for tissue repair and regenerative medicine, there is a lack of evidence to support their clinical use, particularly in human trials. The review concludes that more research is needed to determine the safety and efficacy of these peptides.
Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, but human data is extremely limited, with only three pilot studies conducted. The review concludes that BPC-157 should be considered investigational and its use approached with caution until well-designed clinical trials are conducted.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
This systematic review suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries, with preclinical studies showing improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries. However, the review highlights the need for further clinical safety data and notes that adverse effects are possible due to unregulated manufacturing or contamination.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
This review summarizes the biological activities of BPC 157, a peptide with potential therapeutic benefits for various medical conditions, including tissue injury and inflammatory bowel disease. The review highlights the need for comprehensive clinical studies to confirm its health benefits in humans.
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
This study found that many businesses in Colorado are advertising compounded glucagon-like peptide-1 products for weight loss, including some that make misleading claims about regulatory approval. One product was advertised as compounded with BPC-157, which the FDA has determined is unsafe for compounding.
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
This pilot study found that a single injection of BPC-157 around the area of inflammation in the bladder resulted in complete resolution of symptoms in 10 out of 12 patients with moderate to severe interstitial cystitis who did not respond to pentosan polysulfate treatment. The remaining 2 patients reported significant improvement, with 80% of their symptoms resolved.
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
BPC-157 promotes angiogenesis by increasing the expression and internalization of VEGFR2, and activating the VEGFR2-Akt-eNOS signaling pathway. This study demonstrates the therapeutic potential of BPC-157 in promoting blood flow recovery and vessel formation in ischemic tissues.
Recent research
Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.
This review suggests that BPC 157 may serve as a cytoprotective mediator to counteract both hemorrhage and thrombosis, and promote wound healing and arrhythmia control. The paper concludes that BPC 157 has a unique ability to provide full cytoprotective effects, unlike conventional agents which offer only partial protection.
Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.
This review concludes that BPC-157 has therapeutic potential in addressing electrolyte imbalances, including hyperkalemia, hypokalemia, hypermagnesemia, and hyperlithiemia, by counteracting adverse effects and promoting recovery. The peptide demonstrated comprehensive counteractive effects in various studies, including in vitro and in vivo experiments.
Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.
This review concludes that BPC 157, a stable gastric pentadecapeptide, shows promise in treating complex musculoskeletal and junctional injuries, with efficacy in tendon, ligament, and muscle healing. BPC 157 appears to have a full cytoprotection range and can be administered systemically or locally without a carrier.
Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats.
This study found that BPC 157 therapy produced rapid molecular changes in the aortic wall of rats after unilateral adrenalectomy, leading to a more structurally stable and functionally favorable state. The changes were observed through Fourier transform infrared spectroscopy and suggest early extracellular matrix reinforcement and membrane preservation.
Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats.
BPC-157 therapy was shown to rapidly reverse tracheocutaneous fistula in rats by acting through the NO system, leading to healing of skin and tracheal defects and fistula closure. The therapy also counteracted the negative effects of NO system blockade and immobilization.
Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy.
This review introduces a novel conceptual framework for evaluating corneal ulcer therapy and highlights the potential of BPC-157 as a cytoprotective agent in promoting healing and reducing complications. The framework also suggests that BPC-157 may have benefits in treating glaucoma and promoting tendon healing.
The three channels
We don't endorse any of these. We're describing what exists so you can evaluate the trade-offs honestly.
Compounding pharmacies
US · narrowPre-October 2023, US 503A pharmacies were the most legitimate route — a licensed clinician would prescribe, and the pharmacy would compound from a USP-grade bulk API. After the FDA Category 2 placement, this is largely closed. A few pharmacies still offer it under specific exemptions (patient-specific, drug-shortage rationale), but most major networks have stopped production.
- ·Most large networks (Empower, Tailor Made, Belmar) ended BPC-157 in 2024.
- ·Anything advertised as "503A compounded BPC-157" today is a regulatory edge case — verify the prescriber's license and the pharmacy's accreditation (e.g. PCAB).
Telehealth peptide clinics
Variable complianceA small number of telehealth platforms operate clinics with US-licensed prescribers. After the FDA decision, compliant clinics dropped BPC-157 entirely; less-compliant operators continue selling it via creative legal interpretations — frequently routing prescriptions through foreign pharmacies. Quality and price vary widely.
- ·If they ship without a real licensed prescriber consultation, that's a red flag.
- ·Foreign-routed prescriptions can be seized at customs (it's still federally unapproved).
- ·Verify the pharmacy is actually licensed and the peptide has a Certificate of Analysis (COA).
Research-grade vendors
Gray market · highest riskThe largest channel by volume. Vendors sell BPC-157 powder "for research only — not for human use," exploiting the regulatory ambiguity around research chemicals. Customers self-reconstitute and self-administer. Quality control is entirely on the buyer; some vendors publish third-party HPLC purity reports, most don't.
- ·No oversight of purity, potency, or contamination — independent testing varies wildly.
- ·Customs can seize shipments. Some vendors have been raided / shut down with no recourse for buyers.
- ·Self-injection of unverified substances is a real medical risk (infection, immune response, contaminants).
- ·If you're competing in any sport tested under WADA, this is a doping violation — full stop.
When could BPC-157 become legal?
Honest, opinionated read on the regulatory horizon — based on FDA process timelines, current trial pipeline, and how WADA / TGA precedents typically unfold.
Next 3–6 months
Watching closelyMajor near-term event: FDA's Pharmacy Compounding Advisory Committee reviews BPC-157 on July 23, 2026 for potential Category 1 inclusion on the 503A list. A positive vote would be the first signal that compounding pharmacy access could reopen. Even a positive vote is non-binding — formal rulemaking would take 12+ months before pharmacies could legally compound. Watch the FDA-2025-N-6895 docket.
12–18 months
ConditionalIf PCAC recommends Category 1 AND FDA accepts: rulemaking could conclude and compounding pharmacies could resume making BPC-157 from compliant bulk APIs. Pricing would normalize; supply would stabilize. If PCAC declines or FDA rejects: status quo of telehealth + research-grade vendors continues, with the gray-market dynamic indefinitely.
3–5 years
Plausible (narrow)A specific indication (gut healing, post-surgical recovery, ulcerative colitis adjunct) might receive limited clinical authorisation in some jurisdictions if Phase II/III data emerges. Even in that case, prescription would be tightly scoped — not the broad "recovery peptide" use case currently driving demand.
5–10 years
Plausible (broad)If multiple indications get approval, BPC-157 could become a genuinely-prescribed peptide, sold via standard pharmacies. Whether the WADA ban lifts depends on whether sport-relevant doses are within therapeutic range. The TGA Schedule 10 placement in Australia is harder to reverse; AU access likely remains the slowest to liberalize.
This is informed speculation, not prediction. We'll update this section whenever new FDA notices, clinical trial registrations, or scheduling decisions appear in the timeline above.